Expected to recover at a rapid pace with several chronic disorders such as renal failure, cancer, stroke, Alzheimer’s disease and angina over the last decade that can be treated only in hospitals
According to a new market report published by Transparency Market Research “Hospital Pharmaceuticals Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 – 2020” the global hospital pharmaceuticals market was valued at USD 26.5 billion in 2013 and is estimated to reach USD 11.6 billion by 2020 declining with a CAGR
of (10.5) percent from 2014 to 2020.
The report defines hospital pharmaceuticals as drugs that are exclusively administered in hospital and professional healthcare facilities that encompass both in-patient as well as out-patient departments. Hospital pharmaceuticals market which had been experiencing slumps in past three to four years due to economic slowdown, patent and exclusivity loss of various orphan and blockbuster drugs is expected to recover at a rapid pace. Over a decade there has been a considerable rise in several chronic disorders that can only be treated in hospital setting such as renal failure, canter, stroke, Alzheimer’s disease and angina which is expected to boost hospital pharmaceuticals market in forthcoming years.
The report studies the hospital pharmaceuticals market from two perspectives: major therapeutic class and indications. Market by therapeutic class includes all major drug classes that are majorly prescribed and sold in hospital pharmacies. Market by indication is segmented into six major disorders: cardiology, oncology, nephrology and urology, neurology, pain and anti-infectives. Among the mentioned indications, oncology and cardiology are key markets share declining at a CAGR of (13.01) percent and (9.38) percent respectively.
Decline in growth rate for both the markets is majorly attributed to increasing number of drugs losing their exclusivity during the forecast period (2014-2020). Billion dollar cardiovascular medicines that are getting off patent include Exforge HCT amlodipine/hydrochlorothiazide/valsartan), Benicar HCT (hydrochlorothiazide and olmesartan) and VESIcare (Solifenacin Succinate) in 2014, 2016 and 2018 respectively.Furthermore various billion dollar oncology drugs which will get off patent in next 5 years comprise Gleevec (Imatinib Mesylate), Tarceva (erlotinib), Zytiga (Abiraterone Acetate) and Velcade (bortezomib).
Rise in emergency department visits and increased per capita spending of patients across the globe are some of the major drivers escalating the growth of the overall market. Emergency department visits accounted for 7.4 percent of the total hospital visits in the U.S. in 2011 compared to 2.3 percent in 2010. Healthcare Cost and Utilization Project (HCUP)
statistical brief data estimated that emergency department discharges increased five times (359 patients per 1,000 people) in the U.S. in 2011 compared to 2010.
A large number of new molecular entities are also anticipated to be launched during the forecast period. These primarily include therapeutic areas such as cancer, neurological disorders, infections and cardiovascular diseases. All these factors would increase the global spending on medicines. Moreover, global spending on medicines is expected to increase from USD 1 trillion in 2014 to USD 1.2 trillion by 2017. Such factors are expected to boost the market for hospital pharmaceuticals market especially in case of generic drugs.
Geographically, North America market accounted for the largest share in 2013 due to favorable reimbursement policies, high awareness, rising per capita income, increased spending on the healthcare and greater depth of marketing efforts by key players. Total spending on healthcare in the U.S. increased from USD 320 million in 2012 to USD 330 million in 2013 depicting an increase of per capita spending by 1 percent. Presence of sound intellectual property in the European Union countries and presence of high quality pharmaceutical research organizations are among the few prominent drivers. Whereas,fragmented pricing system and improper reimbursement scenario and regulatory framework for clinical trials are key restraints to the European hospital pharmaceuticals market. Asia Pacific and Rest of the World are among the fastest growing markets for hospital pharmaceuticals due to the presence of large population base, aging population suffering from chronic diseases and increasing disposable income.
EH News Bureau–Mumbai